Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone breathing game help Alpha-1 patients breathe easier?

NCT ID NCT07242079

Symptom relief Sponsor: University of Parma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a simple, home-based breathing technique called the Active Cycle of Breathing Technique (ACBT) with augmented reality support in 50 adults with Alpha-1 antitrypsin deficiency. Participants did the breathing exercises twice daily and walked at least 5000 steps per day for six weeks. The goal was to see if using augmented reality helps patients stick with the program and feel more satisfied, while also tracking changes in breathlessness, lung function, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Active Cycle of Breathing Technique (ACBT) with augmented reality support
What this could lead to
If successful, this approach could offer a simple, home-based way to improve breathing, exercise capacity, and quality of life for people with Alpha-1 antitrypsin deficiency.
What could go wrong
This is a small, observational study with only 50 participants, so results may not apply to everyone. The main goal is to measure satisfaction and adherence, not to prove the technique works better than standard rehab.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

50 people

The number who actually took part.

Started

Nov 2024

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The population will consist of 50 adult patients, referred at outpatient clinic of the Respiratory Disease Unit of the University Hospital of Parma (Italy)

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female adults aged ≥18 years; * Signed informed consent; * All AATD patients, regardless of nephelometric alpha-1 antitrypsin dose and clinical phenotype, who require PR according to guidelines Exclusion Criteria: * Subjects unable to perform the lung function tests and rehabilitation program required by the protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alpha-1 antitrypsin deficiency (AATD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alpha 1-antitrypsin deficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alpha-1 antitrypsin deficiency (AATD)

Contacts and locations

Locations

  • University of Parma

    Parma, Italy, 43126, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.